– USA, TX – Castle Biosciences, Inc. (Nasdaq: CSTL), a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, today announced the appointment of Tiffany Olson to its board of directors, effective immediately.
“We are pleased to welcome Tiffany to our board,” said CEO, Derek Maetzold. “Her leadership and experience as an executive in various public diagnostic companies provides her expertise in the operations of high-growth organizations like Castle and will bring valuable insight to the board.”
About Tiffany Olson
Tiffany Olson, since 2013, has served as president of Nuclear & Precision Health Solutions at Cardinal Health, which develops, manufactures, compounds, dispenses, and delivers 12 million time-critical, patient-specific doses annually to thousands of customers via a network of nuclear pharmacies and manufacturing sites that span the U.S. Before Cardinal Health, Olson was president of NaviMed, a company focused on personalizing medicine through innovative diagnostics. She also worked for Eli Lilly and Company, where she was tasked with leading the effort to formulate the strategy to create and commercialize diagnostics and companion diagnostics. Olson also worked for Roche Diagnostics, where she attained the position of president and chief executive officer of Roche Diagnostics Corporation. She was the first woman to receive the Life Science Alley Luminary Award, recognizing her “rich career in medical diagnostics…exceptional reputation as a leader and her vision to drive both innovation and value for personalized medicine.”
Olson was recognized as one of the 10 Best Women Leaders of 2020 by Industry Era. In 2013, she received the “Woman of Wellness Award” for her extraordinary contributions through her volunteer work in oncology. She currently serves as an ambassador with the American Cancer Society through the ResearcHERS: Women Fighting Cancer campaign, which helps fund women-led cancer research. She has written several articles on personalized medicine, molecular diagnostics, and business strategy. Olson has a bachelor’s degree in business from the University of Minnesota and a master’s degree from St. Thomas University in Minnesota. She has held several board positions and currently serves as a board member of the Council on Radionuclides and Radiopharmaceuticals, Inc.
About Castle Biosciences
About Castle Biosciences
Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma, cutaneous squamous cell carcinoma, suspicious pigmented lesions, and uveal melanoma. For more information about Castle’s gene expression profile tests Castle also has active research and development programs for tests in other dermatologic diseases with a high clinical need. Castle Biosciences is based in Friendswood, Texas, and has laboratory operations in Phoenix, Arizona.
For more information: https://www.castlebiosciences.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
